Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piccaluga, P.
Right arrow Articles by Martinelli, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piccaluga, P.
Right arrow Articles by Martinelli, G
Haematologica, Vol 89, Issue 10, 1269-1271
Copyright © 2004 by Ferrata Storti Foundation

Letter

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients

PP Piccaluga, M Malagola, M Amabile, M Rondoni, S Paolini, F Pane, D Russo, G Visani, M Baccarani, and G Martinelli

Using quantitative reverse-transcription polymerase chain reaction we investigated the significance of achieving molecular complete remission (CR) in 12 patients with bcr/abl-positive acute lymphocytic leukemia treated with imatinib. The 6 patients who achieved molecular CR had significantly better relapse-free survival (RFS) than the others (9 vs 4 months) (p=0.000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio <2 after 4 weeks of treatment had significantly better RFS (10.5 vs 4 months) (p=0.004).




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.